High Triglycerides Signal Hidden Heart Risk, but Effective Treatments Remain Limited
November 16, 2026
The International Atherosclerosis Society consensus describes hypertriglyceridaemia as an underdiagnosed and undertreated marker of residual cardiovascular risk, driven mainly by cholesterol carried in triglyceride-rich remnant particles—not by triglyceride molecules themselves.
The condition affects an estimated 29% of adults worldwide and more than 40% in Latin America, yet INTERASPIRE data show just 2% of patients with elevated triglycerides were receiving triglyceride-specific medication.
The consensus classifies triglyceride levels below 150 mg/dL as normal and levels of 500 mg/dL or higher as severe, with the latter carrying a high risk of acute pancreatitis; clinicians should also investigate lifestyle, medications, genetic factors, and secondary conditions such as insulin resistance, endocrine disorders, and metabolic dysfunction-associated steatotic liver disease.
Because high triglycerides can make LDL-cholesterol estimates unreliable, the consensus recommends assessing non-HDL cholesterol, apolipoprotein B, and remnant cholesterol to better gauge atherogenic particles and residual risk.
Randomized trials have not established that lowering triglycerides itself reduces major cardiovascular events, so elevated levels should prompt broader assessment and management of atherosclerotic risk.
When lipid-lowering treatment is needed, statins are the priority because they reduce cardiovascular risk and LDL cholesterol while typically lowering triglycerides by 10%–30% and helping clear remnant particles.
Lifestyle changes are central: the consensus recommends regular aerobic and strength exercise, cutting excess calories, refined sugars, simple carbohydrates, and saturated fats, and eating more vegetables, legumes, and fish; losing 5%–10% of body weight can lower triglycerides by about 20%.
For severe hypertriglyceridaemia, strict alcohol abstinence and a very-low-fat diet are recommended to reduce pancreatitis risk.
Fibrates are not recommended for primary cardiovascular risk reduction in patients with mild-to-moderate hypertriglyceridaemia who are already taking statins, based on trials including ACCORD and PROMINENT; they may be considered in severe cases to lower triglycerides, although evidence that they prevent pancreatitis is limited.
The consensus discourages over-the-counter fish oil supplements, and trials of combined DHA and EPA have not shown cardiovascular benefit; purified EPA, or icosapent ethyl, may be considered for selected high-risk patients, though the REDUCE-IT mineral-oil placebo has prompted debate and treatment can raise atrial fibrillation and bleeding risks.
ApoC-III-targeting therapies olezarsen and plozasiran have reduced triglycerides and acute pancreatitis incidence and have received approval for familial chylomicronaemia syndrome, while ANGPTL3-targeting drugs and FGF21 analogues remain under investigation.
The consensus calls gene-silencing therapies a major advance for severe disease, but says effective drug strategies to address residual cardiovascular risk in mild-to-moderate hypertriglyceridaemia remain an unmet need.
Summary based on 1 source
Get a daily email with more Science stories
Source

BIOENGINEER.ORG • Nov 15, 2026
International Experts Consensus Statement Targets Management of